314 related articles for article (PubMed ID: 27997549)
1. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
2. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
Eleveld TF; Oldridge DA; Bernard V; Koster J; Colmet Daage L; Diskin SJ; Schild L; Bentahar NB; Bellini A; Chicard M; Lapouble E; Combaret V; Legoix-Né P; Michon J; Pugh TJ; Hart LS; Rader J; Attiyeh EF; Wei JS; Zhang S; Naranjo A; Gastier-Foster JM; Hogarty MD; Asgharzadeh S; Smith MA; Guidry Auvil JM; Watkins TB; Zwijnenburg DA; Ebus ME; van Sluis P; Hakkert A; van Wezel E; van der Schoot CE; Westerhout EM; Schulte JH; Tytgat GA; Dolman ME; Janoueix-Lerosey I; Gerhard DS; Caron HN; Delattre O; Khan J; Versteeg R; Schleiermacher G; Molenaar JJ; Maris JM
Nat Genet; 2015 Aug; 47(8):864-71. PubMed ID: 26121087
[TBL] [Abstract][Full Text] [Related]
3. Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis.
Bellini A; Bernard V; Leroy Q; Rio Frio T; Pierron G; Combaret V; Lapouble E; Clement N; Rubie H; Thebaud E; Chastagner P; Defachelles AS; Bergeron C; Buchbinder N; Taque S; Auvrignon A; Valteau-Couanet D; Michon J; Janoueix-Lerosey I; Delattre O; Schleiermacher G
Clin Cancer Res; 2015 Nov; 21(21):4913-21. PubMed ID: 26059187
[TBL] [Abstract][Full Text] [Related]
4. Emergence of new ALK mutations at relapse of neuroblastoma.
Schleiermacher G; Javanmardi N; Bernard V; Leroy Q; Cappo J; Rio Frio T; Pierron G; Lapouble E; Combaret V; Speleman F; de Wilde B; Djos A; Ora I; Hedborg F; Träger C; Holmqvist BM; Abrahamsson J; Peuchmaur M; Michon J; Janoueix-Lerosey I; Kogner P; Delattre O; Martinsson T
J Clin Oncol; 2014 Sep; 32(25):2727-34. PubMed ID: 25071110
[TBL] [Abstract][Full Text] [Related]
5.
Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
[TBL] [Abstract][Full Text] [Related]
6. Genomic ALK alterations in primary and relapsed neuroblastoma.
Rosswog C; Fassunke J; Ernst A; Schömig-Markiefka B; Merkelbach-Bruse S; Bartenhagen C; Cartolano M; Ackermann S; Theissen J; Blattner-Johnson M; Jones B; Schramm K; Altmüller J; Nürnberg P; Ortmann M; Berthold F; Peifer M; Büttner R; Westermann F; Schulte JH; Simon T; Hero B; Fischer M
Br J Cancer; 2023 Apr; 128(8):1559-1571. PubMed ID: 36807339
[TBL] [Abstract][Full Text] [Related]
7. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma.
Schulte JH; Bachmann HS; Brockmeyer B; Depreter K; Oberthür A; Ackermann S; Kahlert Y; Pajtler K; Theissen J; Westermann F; Vandesompele J; Speleman F; Berthold F; Eggert A; Brors B; Hero B; Schramm A; Fischer M
Clin Cancer Res; 2011 Aug; 17(15):5082-92. PubMed ID: 21632861
[TBL] [Abstract][Full Text] [Related]
8. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
[TBL] [Abstract][Full Text] [Related]
9. Loss of ALK hotspot mutations in relapsed neuroblastoma.
Allinson LM; Potts A; Goodman A; Bown N; Bashton M; Thompson D; Basta NO; Gabriel AS; McCorkindale M; Ng A; McNally RJQ; Tweddle DA
Genes Chromosomes Cancer; 2022 Dec; 61(12):747-753. PubMed ID: 36029175
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic anaplastic lymphoma kinase (ALK) mutation in neuroblastomas and other pediatric tumors.
Kwon MJ; Choi YL; Sung KW; Kang SY; Park SM; Choi SY; Kim JS; Suh YL
Pathol Res Pract; 2011 Oct; 207(10):634-9. PubMed ID: 21940108
[TBL] [Abstract][Full Text] [Related]
11. Clinical feature of anaplastic lymphoma kinase-mutated neuroblastoma.
Ogura T; Hiyama E; Kamei N; Kamimatsuse A; Ueda Y; Ogura K
J Pediatr Surg; 2012 Oct; 47(10):1789-96. PubMed ID: 23084186
[TBL] [Abstract][Full Text] [Related]
12. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.
Chen L; Humphreys A; Turnbull L; Bellini A; Schleiermacher G; Salwen H; Cohn SL; Bown N; Tweddle DA
Oncotarget; 2016 Dec; 7(52):87301-87311. PubMed ID: 27888620
[TBL] [Abstract][Full Text] [Related]
13. Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
Javanmardi N; Fransson S; Djos A; Sjöberg RM; Nilsson S; Truvé K; Kogner P; Martinsson T
Sci Rep; 2019 Feb; 9(1):2199. PubMed ID: 30778092
[TBL] [Abstract][Full Text] [Related]
14. Seek and Ye Shall Find: Subclonal Anaplastic Lymphoma Kinase Mutations.
George RE
Clin Cancer Res; 2015 Nov; 21(21):4747-9. PubMed ID: 26362998
[TBL] [Abstract][Full Text] [Related]
15. RAS-MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma.
Eleveld TF; Schild L; Koster J; Zwijnenburg DA; Alles LK; Ebus ME; Volckmann R; Tijtgat GA; van Sluis P; Versteeg R; Molenaar JJ
Cancer Res; 2018 Nov; 78(21):6297-6307. PubMed ID: 30115695
[TBL] [Abstract][Full Text] [Related]
16. [ALK gene mutations in childhood neuroblastoma].
Yang CL; Yue LJ; Jiang XP; Wen FQ; Zheng MM
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Oct; 14(10):763-6. PubMed ID: 23092569
[TBL] [Abstract][Full Text] [Related]
17. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
[TBL] [Abstract][Full Text] [Related]
18. Targeted Therapy for Neuroblastoma: ALK Inhibitors.
Schulte JH; Schulte S; Heukamp LC; Astrahantseff K; Stephan H; Fischer M; Schramm A; Eggert A
Klin Padiatr; 2013 Nov; 225(6):303-8. PubMed ID: 24166094
[TBL] [Abstract][Full Text] [Related]
19. Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas.
Yan B; Kuick CH; Lim M; Venkataraman K; Tennakoon C; Loh E; Lian D; Leong MY; Lakshmanan M; Tergaonkar V; Sung WK; Soh SY; Chang KT
PLoS One; 2014; 9(9):e106575. PubMed ID: 25188507
[TBL] [Abstract][Full Text] [Related]
20. Too many targets, not enough patients: rethinking neuroblastoma clinical trials.
Fletcher JI; Ziegler DS; Trahair TN; Marshall GM; Haber M; Norris MD
Nat Rev Cancer; 2018 Jun; 18(6):389-400. PubMed ID: 29632319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]